Thursday, November 19, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 52

Humacyte Files FDA Application to Add Dialysis Access as Second ATEV Use

Humacyte has submitted a supplemental Biologics License Application to the FDA, aiming to clear its bioengineered ATEV vessel for arteriovenous access in hemodialysis patients. It would be the second approved indication for the product, after Symvess won clearance for vascular trauma in December 2024.

By the Paparazzi desk November 19, 2026 · 5:01 AM · finance.yahoo.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: finance.yahoo.com.
  • The source published it on Nov 19, 2026 at 5:01 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Humacyte, Inc. (Nasdaq: HUMA) said it submitted the sBLA to the U.S. Food and Drug Administration for its acellular tissue engineered vessel, or ATEV, seeking approval in arteriovenous access for hemodialysis. The filing targets patients with end-stage kidney disease who face an increased risk of AV fistula maturation failure. If cleared, dialysis access would become the ATEV's second approved indication.

The Durham, North Carolina-based company already has one approval in hand: the FDA greenlit the ATEV under the brand name Symvess in December 2024 for extremity vascular trauma. Humacyte describes itself as a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale.

Sponsored

The application leans on three Phase 3 studies in hemodialysis access. In the recently reported V012 Phase 3 trial, women implanted with the ATEV reached functional access more than three months sooner than women who received an AV fistula, the current standard of care, and spent significantly more time free of dialysis catheters over the first year. Women have historically seen poorer AV fistula outcomes, including higher maturation failure rates, longer waits for functional access and heavier reliance on infection-prone catheters.

CEO and co-founder Laura Niklason framed the filing around those patients. "For too long, patients on dialysis, and women in particular, have had to settle for access options that often do not work well for them," she said. "We are excited about the potential of the ATEV to provide a new potential vascular access option for hemodialysis patients in need."

Humacyte says the ATEV would be the first new option for patients needing alternative hemodialysis access in decades. The company pitches it as a ready-to-use biologic conduit that has performed predictably in patients with small vessel anatomy, diabetes or obesity, factors that complicate AV fistula maturation. Nearly 500,000 Americans currently depend on hemodialysis for survival, according to the company.

TopicsHumacyte · HUMA · FDA · ATEV · Symvess · Laura Niklason · end-stage kidney disease · hemodialysis

Share

Source: finance.yahoo.com

Written by AI from verified reporting.

More stories

  • Health & science 13:01 UTC · 2 hours ago · technologyreview.com · 0 views
    Donated liver survives seven weeks outside the body in Sydney record
  • Health & science 12:31 UTC · 2 hours ago · finance.yahoo.com · 0 views
    Sanofi's next-gen rabies shot VaxRabeo scores EU approval
  • Health & science 11:45 UTC · 3 hours ago · reuters.com · Caught by @mimi💕💕 · 1 view
    AbbVie Bets Up to $2.54B on Disco's Next-Gen Cancer Drugs
  • Health & science 11:45 UTC · 3 hours ago · fnob.it · 1 view
    TenK10K maps 5 million immune cells, linking DNA variants to 16 diseases
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.